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ABSTRACT 
SPROUTY-2 (SPRY2) is a modulator of tyrosine kinase receptor signaling with 
receptor- and cell type-dependent inhibitory or enhancing effects. Studies on the action 
of SPRY2 in major cancers are conflicting and its role remains unclear. Here we have 
dissected SPRY2 action in human colon cancer. Global transcriptomic analyses show 
that SPRY2 downregulates genes encoding tight junction proteins such as claudin-7 and 
occludin and other cell-to-cell and cell-to-matrix adhesion molecules in human SW480-
ADH colon carcinoma cells. Moreover, SPRY2 represses LLGLL2/HUGL2, 
PATJ1/INADL and ST14, main regulators of the polarized epithelial phenotype, and 
ESRP1, an epithelial-to-mesenchymal transition (EMT) inhibitor. A key action of 
SPRY2 is the upregulation of the major EMT inducer ZEB1, as these effects are 
reversed by ZEB1 knock-down by means of RNA interference. Consistently, we found 
an inverse correlation between the expression level of claudin-7 and those of SPRY2 
and ZEB1 in human colon tumors. Mechanistically, ZEB1 upregulation by SPRY2 
results from the combined induction of ETS1 transcription factor and the repression of 
microRNAs (miR-200 family, miR-150) that target ZEB1 RNA. Moreover, SPRY2 
increased AKT activation by epidermal growth factor (EGF) whereas AKT and also Src 
inhibition reduced the induction of ZEB1. Altogether, these data suggest that AKT and 
Src are implicated in SPRY2 action. Collectively, these results show a tumorigenic role 
of SPRY2 in colon cancer that is based on the dysregulation of tight junction and 
epithelial polarity master genes via upregulation of ZEB1. The dissection of the 
mechanism of action of SPRY2 in colon cancer cells is important to understand the 
upregulation of this gene in a subset of patients with this neoplasia that have poor 
prognosis. 
Keywords: SPROUTY-2, colon cancer, ZEB1, AKT, ETS1, claudin-7  
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INTRODUCTION 
SPROUTY-2 (SPRY2) belongs to a family of intracellular modulators of tyrosine 
kinase receptor signaling.1,2 SPRY2 action is receptor- and cell type-dependent: it 
inhibits signaling by activated fibroblast growth factor receptor (FGFR) and vascular 
endothelial growth factor receptor (VEGF) whereas it increases signaling by epidermal 
growth factor receptor (EGFR) in some cell types.3,4 The underlying mechanisms 
include the inhibition of EGFR ubiquitination-dependent degradation and trafficking 
from early to late endosomes.5,6 
Given the important role of EGFR and FGFRs on the biology of many epithelial 
cell types and as therapeutic targets in carcinomas and other cancers, SPRY2 is drawing 
increasing attention. However, the role of SPRY2 in cancer remains unclear.2 In colon 
cancer, we have previously reported SPRY2 upregulation in high-grade tumors and at 
the invasion front of low-grade tumors.7 Likewise, SPRY2 RNA and protein levels are 
higher in colon adenocarcinomas than in normal adjacent mucosa.8 In SW480-ADH 
colon cancer cells SPRY2 represses CDH1/E-cadherin and counteracts the adhesive 
phenotype induced by 1α,25-dihydroxyvitamin D3.7 Moreover, in HT-29 and LS-174T 
cells SPRY2 increases the level of c-MET and HGF-stimulated ERK and AKT 
phosphorylation, promoting cell migration and invasion.8 Further supporting a 
tumorigenic role, SPRY2 is upregulated in KRAS mutant colorectal cancer,9 and in 
melanoma cells harbouring N-RAS or B-RAF mutations.10,11 RNA expression repository 
databases show upregulation of SPRY2 expression in colorectal tumors versus others 
neoplasias.12 Consistently, we have recently shown that SPRY2 is a target of β-
catenin/FOXO3a, a marker of poor prognosis in colon cancer.13 In contrast, lower levels 
of SPRY2 RNA have been reported in tumor versus normal tissue and in stage III/IV 
versus stage II colon cancer patients, as well as inhibitory effects of exogenous SPRY2 
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overexpression on the proliferation, migration and tumorigenic potential of HCT116 
colon cancer cells xenografted in immunodeficient mice.14 Also, SPRY2 appears to 
have tumor suppressive effects in breast, prostate, and liver cancers and in B-cell diffuse 
lymphoma.15-19 These opposite effects are indicative of cell-type-dependent activities of 
SPRY2.2 
To dissect the action of SPRY2 in colon cancer, we analyzed its effects on gene 
expression and phenotype of SW480-ADH cells. Transcriptomic analyses revealed the 
repression by SPRY2 of genes encoding proteins involved in cell-to-cell and cell-to-
matrix adhesion or regulating epithelial cell polarity such as ST14, which codes for the 
membrane-anchored serine protease matriptase that is essential for the integrity of the 
intestinal epithelial barrier.20 We show that most of the gene regulatory effects of 
SPRY2 are mediated by ZEB1, a major epithelial-to-mesenchymal transition (EMT) 
inducer. Thus, SPRY2 is a potent inhibitor of the epithelial phenotype in colon 
carcinoma cells by repressing tight junction and polarity regulators through the 
upregulation of ZEB1, which in turn results from the induction of the transcription 
factor ETS1 and the downregulation of micro(mi)RNAs (miR200 family, miR-150) that 
target ZEB1 RNA. 
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RESULTS 
SPRY2 represses epithelial adhesion and polarity genes 
To characterize the effects and dissect the mechanism of action of SPRY2 in colon 
carcinoma cells we generated SW480-ADH cells (containing low level of endogenous 
SPRY2 protein) stably expressing a wild type (AU5-tagged) SPRY2 (SPRY2-wt cells). 
We also generated cells expressing mutant S112A (SPRY2-S112A cells) or Y55F 
(SPRY2-Y55F cells) SPRY2 proteins, which respectively lack the phosphorylation site 
for Mnk1/2 kinases (Ser112) or a tyrosine residue (Tyr55) thought to be required for the 
interaction with c-Cbl and thus for potentiation of EGFR stability as well as for full 
FGF inhibitory activity.21-24 Empty vector transfected cells (Mock) were used as control. 
All cell types had a similar polygonal morphology except SPRY2-Y55F cells that 
appeared more elongated (Figure 1a, left). Expression of exogenous SPRY2 proteins 
was confirmed by Western blot (Figure 1a, right). 
 To get insight into the mechanisms through which SPRY2 impacts on gene 
expression, we carried out a global transcriptomic analysis of the four transfectants. 
High correlation was observed between replicates (Supplementary Table 1), while 
SPRY2-wt and SPRY2-S112A have the lowest correlations between conditions. 
Samples were unambiguously clusterized by transfected type in a Principal Component 
Analysis (PCA) explaining most of the variance (99,7%) (Supplementary Figure S1). 
Furthermore, Single Enrichment Analysis (SEA) with differentially expressed 
transcripts (Supplementary Table 2) showed that genes related with cell-to-cell and cell-
to-matrix adhesion were highly represented in the comparisons except for Mock vs 
SPRY2-S112A (Supplementary Table 3). These findings were also supported by a Gene 
Set Enrichment Analysis (GSEA) on adhesion-related KEGG and GO pathways (Figure 
2). Our previous studies showed the capacity of SPRY2 to inhibit the expression of 
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CDH1/E-cadherin causing loss of intercellular adhesion.7 Additionally, SPRY2 is 
preferentially expressed in cells at invasion front of human colon tumors in vivo.7 These 
results, together with data from in silico analyses, led us to perform a detailed 
inspection of genes related to adhesion structures and pathways. 
 As compared to Mock cells, SPRY2-wt cells showed lower expression levels of 
genes encoding adherens junctions proteins (CDH1, CDH3), tight junctions proteins 
(CLDN7/claudin-7, OCLN/occludin) and other adhesion molecules (GJB2, NCAM, 
JUP/CTNNG) (Supplementary Table 2). Conversely, SPRY2-wt cells expressed higher 
level of ZEB1 and CLDN1/claudin-1, which has been proposed to be protumorigenic in 
colon cancer.25 SPRY2-wt cells showed also reduced expression of several genes 
encoding integrins (ITGB8, ITGB4, ITGB2, ITGB6) and extracellular matrix proteins 
(TNC, LAMB3, LAMC2, LAMA3). Downregulation of CLDN7 and OCLN and 
upregulation of CLDN1 and ZEB1 in SPRY2-wt and SPRY2-Y55F cells were validated 
by qRT-PCR and Western blot (Figures 1b and c), using the reported inhibition of 
CDH1/E-cadherin as control.7 GSEA revealed that the expression profiles of genes 
encoding adhesion and extracellular matrix proteins were significantly enriched in 
SPRY2-S112A cells and Mock cells compared to SPRY2-wt (Figure 2). 
 Further supporting a role of SPRY2 disrupting tight junction functionality and 
cell polarity, our transcriptomic study showed also reduced expression in SPRY2-wt 
and SPRY2-Y55 cells of LLGL2/HUGL2, INADL/PATJ1 and ST14, polarity genes that 
promote tight junction formation and function as tumor suppressors (Supplementary 
Table 2 and Figures 1d and e).20,26-28 SPRY2 represses also Epithelial Cell Adhesion 
Molecule (EPCAM) gene that is mutated in a proportion of Hereditary Non-Polyposis 
Colorectal Cancer patients and whose overexpression has tumor type-dependent effects 
on patient survival (Figures 1d and e).29 EpCAM protein binds claudin-1 and claudin-7 
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and regulates their dynamics and the function of tight junctions.30,31. Epithelial Splicing 
Regulatory Protein 1 (ESRP1), which encodes a broad splicing regulator in epithelial 
cells that prevents the EMT process,32,33 was strongly downregulated in SPRY2-wt cells 
and, conversely, upregulated in SPRY2-S112A cells (Figure 1d). Consistent with the 
findings described above, the expression levels of ZEB1 and SPRY2 proteins directly 
correlate in a panel of colon carcinoma cell lines (Supplementary Figure S2). 
Collectively, these results indicate that SPRY2 ectopic expression causes loss of the 
epithelial phenotype (adhesiveness and polarity) by controlling multiple genes, and 
highlight the importance of Ser112 for this function. 
To investigate how SPRY2 regulates tight junction genes, we cloned a fragment 
of CLDN7 proximal promoter (-1136/+428 bp) upstream the luciferase reporter gene. 
Overexpression of SPRY2 markedly reduced the activity of CLDN7 promoter (Figure 
1f). ZEB1 is a major inducer of EMT that represses a number of epithelial adhesion 
genes. We found an inverse relation between the expression level of claudin-7 and 
ZEB1 proteins in the four cell types (Figure 1c). Interestingly, ectopic expression of 
ZEB1 inhibited CLDN7 promoter in Mock cells but did not further decrease its activity 
in SPRY2-wt cells, which is consistent with the high level of ZEB1 expression in the 
latter cells (Figure 1f). This supports a major role of ZEB1 in the repression of CLDN7 
by SPRY2. 
 
ZEB1 mediates the repression of epithelial adhesion and polarity genes by SPRY2 
Given that ESRP1, LLGL2/HUGL2 and ST14 genes are repressed by ZEB1 in other 
systems,34-36 we sought to elucidate to what extent the gene regulatory effects of SPRY2 
depend on ZEB1. We knock-downed ZEB1 by transfection of shRNA in Mock cells, as 
confirmed at the RNA and protein levels (Figures 3a and b). ZEB1 downregulation 
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increased CDH1, CLDN7, ST14, OCLDN, and ESRP1 RNA (Figure 3a). Data on 
claudin-7, E-cadherin, ST14 and EpCAM were reproduced at the protein level (Figure 
3b). In agreement with the reciprocal negative feedback loop of regulation described in 
other systems,37-39 ZEB1 knock-down caused the upregulation of miR-200b and miR-
200c (Figure 3c). Similar results were obtained in SPRY2-wt cells in which ZEB1 was 
silenced by lentivirus transduction of ZEB1 shRNA (Figures 3d-f). Moreover, 
interference expression of ZEB1 in SPRY2-wt cells induced CLDN7 and CDH1 
promoters (Figure 3g). Identical results were obtained by using lentiviruses to knock-
down ZEB1 expression in Mock cells (Supplementary Figure S3). These results 
strongly suggest that ZEB1 mediates the dysregulation of tight junction and epithelial 
polarity genes by SPRY2 and that ZEB1 is a probable direct repressor of claudin-7. 
 
Inverse correlation between the expression of SPRY2 and ZEB1 with that of 
claudin-7 in colon tumors 
To explore the relevance of these findings in vivo, we analyzed the expression of 
SPRY2, ZEB1 and claudin-7 in tissue microarrays of tumors of colon cancer patients 
(Figure 4a). Significant positive correlation between the expression of SPRY2 and 
ZEB1 (n = 39, r = 0.63, P < 0.0001) and negative correlation between that of ZEB1 and 
claudin-7 (n = 53, r = -0.36, P = 0.007) and SPRY2 and claudin-7 (n = 34, r = -0.35, P 
= 0.037) were found (Figure 4b). These results were consistent with those obtained in 
cultured cells supporting the idea that the regulation of ZEB1 by SPRY2 and the 
repression of claudin-7 by ZEB1 occur also in vivo in human colon tumors. 
 
Mechanism of ZEB1 upregulation by SPRY2 
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To investigate the mechanism of ZEB1 upregulation by SPRY2 we first studied whether 
this effect could be mediated by the modulation of miRs targeting ZEB1 RNA. An in 
silico analysis of ZEB1-RNA-3’UTR region using three independent target prediction 
algorithms (TargetScan, miRANDA, PicTar) revealed the presence of several putative 
binding sites for evolutionarily conserved miR species: miR-142-3p, miR-23, miR-150, 
miR-342-3p and the previously described miR-200b/c 37-39 (Figure 5a). To examine the 
role of these miRs in ZEB1 RNA regulation by SPRY2, their expression was analyzed 
by qRT-PCR in Mock and SPRY2-wt cells. miR-142-3p, miR-23a and miR-150, and 
also miR-200b, miR-200c, but no miR-342-3p, were expressed at lower level in SPRY2-
wt cells than in Mock cells (Figure 5b). Reduced expression of miR-200b and miR-200c 
was also detected in SPRY2-Y55F cells, but not in SPRY2-S112A cells (Figure 5c). 
To determine whether these miRNAs directly modulate ZEB1 levels, we cloned 
a fragment of ZEB1-RNA-3’UTR containing the putative miRNA-binding sites into the 
psiCHECK2 dual luciferase reporter vector. Co-transfection of HEK293T cells with 
mimic oligonucleotides of miR-200b, miR-142-3p and miR-150, but not miR-23a, 
together with a ZEB1-RNA-3’UTR-luciferase construct, resulted in reduced luciferase 
activity at both low (5 nM) and high (50 nM) amount of transfected oligonucleotides 
(Figure 5d). Moreover, mutation of predicted binding sites for miR-200 family and miR-
150, but not for miR-142-3p (Figure 5e, left), reverted this effect, indicating that miR-
200 and miR-150 are direct modulators of ZEB1 (Figure 5e, right). Transfection of miR-
200b into SPRY2-wt cells reduced the expression of ZEB1 RNA and protein more 
efficiently than the transfection of miR-150 or miR-142-3p using scrambled-transfected 
SPRY2-wt cells and Mock cells as controls (Figures 5f and g). Consistently, only miR-
200b led to upregulation of claudin-7 and E-cadherin (Figure 5g). These results show a 
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preferential regulation of ZEB1 RNA by miR-200 and an additional effect of miR-150, 
and support that the repression of claudin-7 by SPRY2 is mediated by ZEB1. 
To examine whether SPRY2 could control directly the expression of miR-
200b/c, we used luciferase-reporter vectors containing the promoter of miR-200b/a 
(miR-200b-a-429 (-321/+120))40 and miR-200c (hsa-miR-200c promoter (-683/-67)).39 
First, these plasmids were transfected into Mock and SPRY2-wt cells. A stronger 
reduction in the activity of miR-200b/a and miR-200c promoters was found in SPRY2-
wt cells that express SPRY2 constitutively, while transfected ZEB1 expression vector 
further decreased the activity of the two promoters in Mock cells but not in SPRY2-wt 
cells (Figure 5h). Second, ZEB1 and SPRY2 expression vectors were transiently 
transfected in SW480-ADH cells. Exogenous SPRY2 did not change the activity of the 
two miRs promoters and did not affect their inhibition by ZEB1 (Figure 5i, left). These 
results agree with the reported direct inhibition of miR-200b/a and miR-200c promoters 
by ZEB1 and suggest that the effect of SPRY2 is mediated by the upregulation of ZEB1, 
which does not take place at sufficient level upon transient SPRY2 transfection (Figure 
5i, right). 
 Next we studied putative mediators of the upregulation of ZEB1 by SPRY2. 
Given the relation between SPRY2 and EGF signaling3,4 this pathway was chosen for 
detailed study. In concordance with other reports,41 SPRY2-wt did not change the basal 
or EGF-induced levels of active (phosphorylated) ERK (Figure 6a), which may be 
related to the presence of a mutated K-RAS gene in SW480-ADH cells. By contrast, 
SPRY2 amplified the activation of AKT induced by EGF (Figure 6b). Additionally, 
reduction of active phospho(p)-AKT, using wortmannin (PI3K inhibitor) or MK2266 
(AKT inhibitor) decreased the level of ZEB1 (Figure 6c). Likewise, the Src inhibitor 
PP2 decreased ZEB1 expression in Mock and SPRY2-wt cells and increased that of 
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claudin-7 in Mock cells (Figure 6d). Thus, AKT and Src seem to participate in the 
upregulation of ZEB1 by SPRY2. 
 ETS1 mediates the upregulation of ZEB1 by Snail1 in mouse breast epithelial 
cells,42 and our transcriptomic analysis revealed that the RNA level of ETS1 
transcription factor is 1.62-fold higher in SPRY2-wt cells than in Mock cells, while no 
differences were found for ETS2 (Supplementary Table 2). Therefore, we investigated 
its implication in SPRY2 action. First, we confirmed by Western blot analysis the 
presence of higher level of ETS1 protein in SPRY2-wt and SPRY2-Y55F cells than in 
Mock and SPRY2-S112A cells (Figure 6e). Second, transduction of SPRY2-wt cells 
with lentiviruses encoding ETS1 shRNA led to a partial reduction of ZEB1 protein 
expression levels (Figure 6f). Third, in contrast, ETS1 expression was unaffected by 
ZEB1 knock-down in SPRY2-wt cells showing that no reciprocal regulation exists 
(Figure 6g). Fourth, overexpression of ETS1 by transient transfection of an exogenous 
cDNA increased ZEB1 expression (Figure 6h). These results suggest that ETS1 
contributes to the induction of ZEB1 by SPRY2, which is most likely amplified by the 
repression of miR-200 and miR-150 species (Figure 6i).  
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DISCUSSION 
This study shows that SPRY2 triggers a coordinated pattern of gene expression through 
the imbalance of the ZEB1/miR200 switch in favor of ZEB1 upregulation mediated at 
least in part by ETS1 and AKT. This mechanism leads to the loss of polarized and 
adhesive epithelial phenotype. 
 Tight junctions are responsible for epithelial barrier function and polarity, and 
control cell proliferation and differentiation, which are disrupted at early and advanced 
stages of tumorigenesis.43 In particular, downregulation of claudin-7 is an early event in 
colorectal cancer44 and promotes tumorigenesis of colon cancer cells.45,46 Data obtained 
in biopsies from colon cancer patients indicating an inverse relation between ZEB1 and 
claudin-7 expression are consistent with the downregulation of many tight junction and 
polarity genes by SPRY2 in SW480-ADH cells. In addition, they agree with the 
tumorigenic role of ZEB1 and its inverse relation between claudin-7 and other family 
members and ZEB1 in lung cancer.47 Altogether, our results showing repression of tight 
junction proteins by SPRY2 strongly support a protumorigenic action in colon cancer. 
 Notably, mutation of Ser112 residue (SPRY2-S112A cells) abolishes most 
SPRY2 effects on the expression of epithelial genes. The role of this aminoacid in 
SPRY2 activity is controversial. One study has proposed that Ser112 phosphorylation by 
Mnk1, a kinase activated by p38MAPK, stabilizes Spry2 protein in Chinese hamster 
ovary (CHO)-K1 cells.23 In contrast, another study shows that Mnk2 (also a p38MAPK 
substrate) but not Mnk1 phosphorylates SPRY2 leading to its association with the E3 
ubiquitin ligase Nedd4 and posterior degradation in HEK293T cells.24 Likewise, 
p38MAPK decreases Spry2 content in mouse embryo fibroblasts via phosphorylation of 
Siah2 E3 ubiquitin ligase.48 Our results agree with this study as the p38MAPK inhibitor 
SB203080 increased the level of SPRY2 protein in Mock cells (not shown). In addition, 
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our data agree with those of Edwin et al. regarding the similar effects of wild-type and 
Tyr55 SPRY2 proteins.24 Mutation of Tyr55, that has been proposed to generate a 
dominant-negative SPRY2 in terms of inhibition of FGF signaling,21-23 did not affect the 
repression of tight junction or polarity proteins (SPRY2-Y55F cells), indicating that this 
residue is important for only a subset of SPRY2 actions.  
The precise mechanism by which SPRY2 regulates gene expression is not fully 
known. We analyzed the expression of the homeobox SIX1 gene, which is 
overexpressed in colorectal cancer and promotes EMT at least in part via the repression 
of miR-200 family and activation of ZEB1.49 No differences were detected 
(Supplementary Figure S4). By contrast, the longer activation of AKT and the effect of 
AKT and Src inhibition on ZEB1 induction suggest that these two enzymes are 
implicated in SPRY2 action in SW480-ADH cells that, of note, overexpress EGF and 
harbor a mutated K-RAS gene. AKT and Src may contribute to upregulate ETS1, which 
in turn activates ZEB1.42 
 In conclusion, our findings support a key role of SPRY2 promoting the EMT 
process in colon carcinoma cells through ZEB1 induction by a mechanism that implies 
AKT/Src, ETS1 and miR200/miR-150 species (Figure 6i). Why SPRY2 has, instead, 
tumor suppressor activity in other types of cancer cells remains to be elucidated.  
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MATERIALS AND METHODS 
Cells and cell culture 
Human colon carcinoma SW480-ADH and HEK293T embryonal kidney cell lines were 
cultured in RPMI and DMEM plus 10% fetal bovine serum respectively (Life 
technologies, Carlsbad, CA, USA). Cell lines were originally obtained from the 
American Type Culture Collection (ATCC) and authenticated using the GenePrint® 10 
System (Promega, Madison, WI, USA), which allows co-amplification and three-color 
detection of ten human loci: TH01, TPOX, vWA, Amelogenin, CSF1PO, D16S539, 
D7S820, D13S317, D21S11 and D5S818. Short Tandem Repeat profiles were sent for 
comparison against cell line databases (ATCC, DSMZ). Last test was done in February 
2014. SPRY2-wt, SPRY2-S112A and SPRY2-Y55F and Mock cells were generated by 
stable transfection of SW480-ADH cells with pCEFL-KZ-AU5, pCEFL-KZ-AU5-
hSPRY2, pCEFL-KZ-AU5-hSPRY2 S112A or pCEFL-KZ-AU5-hSPRY2 Y55F 
plasmids.50 Cells were tested routinely to ensure there was no mycoplasma 
contamination (Universal Mycoplasma Detection kit, ATCC, Manassas, VA, USA; #30-
1012). 
 
Antibodies and reagents 
We used primary mouse monoclonal antibodies against E-cadherin (BD Transduction 
Laboratories, Franklin Lakes, NJ, USA; #610182), AU5 (Covance, Princeton, NJ, USA; 
MMS-135R), S6 ribosomal protein (Cell Signaling, Danvers, MA, USA; #23175) and 
p-ERK (Santa Cruz Biotechnology, Dallas, TX, USA; sc-7383); rabbit polyclonal 
antibodies against SPRY2 (Upstate, Billerica, MA, USA; #07-524), ETS1 and ERK 2 
(Santa Cruz Biotechnology; sc-350 and sc-154 respectively), ZEB1 (Sigma-Aldrich, St 
Louis, MO, USA; #HPA027524), ST14 (Bethyl, Montgomery, TX, USA; A300-221A), 
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p-AKT (Ser473) (Cell Signaling; #9271), occludin, claudin-7 and claudin-1 (Life 
Technologies; #71-1500; #34-9100; #51-9000), EpCAM (Abcam, Cambridge, UK) and 
p-S6 ribosomal protein (Ser240/244) (Cell Signaling; #2215S); and goat polyclonal 
antibodies against ZEB1, AKT, β-actin and lamin B (Santa Cruz Biotechnology; sc-
10572, sc1618, sc-1616 and sc-6216, respectively). HPR-conjugated secondary 
antibodies were anti-rabbit IgG (H+L) (Jackson Immunoresearch, West Grove, PA, 
USA; 111-035-045), anti-mouse IgG (H+L) (Promega; W402B) and anti-goat IgG 
(Santa Cruz Biotechnology; sc-2020). Secondary antibodies used for Odyssey Infrared 
Imaging were IRDye® 800 donkey anti-mouse IgG (H&L) (Rockland Inc, Gibertsville, 
PA, USA; #610-732-124) and IRDye® 680 donkey anti-rabbit IgG (Rockland Inc.; 
#926-32223). Inhibitors: Src-family tyrosine kinases, PP2 (Tocris, Bristol, UK, #1407); 
PI3K inhibitor, wortmannin (Cell Signaling; #99516), AKT inhibitor, MK2266 
(Selleckchem, Munich, Germany; #S1078). 
 
Cloning of CLDN7/claudin-7 promoter 
A 1.56 kb fragment of the hCLDN7/Claudin-7 promoter (-1136/+428) similar to the one 
described by Kohno and colleagues51 was amplified by PCR using human genomic 
DNA as template, and the following primers: forward 5’-
GACAAGGAGTGAAACAGG-3’ and reverse 5’-TTCCGCCCTCAGAAAACA-3’. 
The resulting product was cloned into the pGEM-T Easy vector (Promega) and 
sequenced. Subsequently, it was released with EcoRI, filled-in using the large fragment 
of E. coli DNA polymerase I (Klenow), and subcloned into the SmaI site of 
promoterless pGL3 basic Firefly luciferase expression vector (Promega). 
 
Reporter assays 
 16
Reporter assays were performed in SW480-ADH, Mock, SPRY2-wt and HEK293T 
cells. Unless otherwise indicated, cells were transfected using the jetPEI reagent 
(PolyPlus Transfection, New York, NY, USA). Firefly (Luc) and Renilla reniformis 
luciferase (Rluc) activities were measured separately using the GloMax® 96 Microplate 
Luminometer (Promega). Luc activity was normalized to the Rluc activity (constitutive 
expression). The promoter constructs for miR-200b/a and miR-200c were generously 
provided by Prof. Gregory Goodall (Center for Cancer Biology, Adelaide, Australia) 
and Prof. Thomas Brabletz (University of Freiburg, Germany), respectively. pCDNA3-
ZEB1 expression plasmid was provided by Dr. Antonio García de Herreros (Instituto 
Municipal de Investigación Médica, Barcelona, Spain). The results are represented as 
the average of the fold induction obtained from three independent experiments using 
quadruplicates. 
3’-UTR Luciferase Assays: A portion of the ZEB1-RNA-3’UTR containing the studied 
putative miRNA binding sites was amplified by PCR using the primers forward 5’-
CTCGAGCACAAAATAAATCCGGGTGTG-3’ and reverse 5’- 
GCGGCCGCAGTCCCTGCAATCAGAACTCA-3’, and cloned into psiCHECK2 
luciferase reporter vector (Promega) using XhoI and NotI. HEK293T cells were seeded 
into 96-well plates (20 x 103 cells/well) and co-transfected (Lipofectamine 2000, Life 
technologies) with the ZEB1-RNA-3’UTR construct and the indicated amounts of 
mimic negative control (scrambled), miR-200b, miR-142-3p, miR-23a and miR-150 
miRIDIAN mimics (Dharmacon). Luciferase activity was measured 24 h later using the 
Dual-Glo Luciferase Assay System (Promega). Rluc activity was normalized to 
corresponding Luc activity and plotted as a percentage of the control. Mutations at the 
putative miRNA binding sites were generated using the QuickChange XL Site-Directed 
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Mutagenesis Kit (Stratagene, La Jolla, CA, USA) following the manufacturer’s 
instructions. Luciferase assays were performed at least three times using triplicates. 
 
RNA interference and overexpression strategies 
ZEB1 knock-down in Mock cells was performed as described.52 ZEB1 silencing in 
SPRY2-wt and Mock cells, and ETS1 silencing in SPRY2-wt cells was carried out using 
the lentiviral vector pGIPz containing different shRNAmir sequences: ZEB1, 
V3LHS_356186 (sh1), V3LHS_356187 (sh2) and V2LHS_226625 (sh3); ETS1, 
V2LHS_244928 (sh1) and V3LHS_301171 (sh2) (Dharmacon, GE Healthcare, 
Pittsburgh, PA, USA). Non-silencing shRNAmir sequence (NS), with no homology to 
known mammalian genes was used as control, cloned in pGIPz vector (Dharmacon). 
Lentiviruses were produced and tittered as previously described,53 and target cells were 
transduced at multiplicity of infection (MOI) of 40. ETS1 overexpression in SW480-
ADH cells was performed by transient transfection of exogenous ETS1 cDNA 
(OriGene, Rockville, MD, USA; #RG227466). 
 
Quantitative RT-PCR 
Total RNA was purified using the NucleoSpin® miRNA extraction kit (Macherey-
Nagel, Düren, Germany). Quantitative real-time PCR (qRT-PCR) analyses of SPRY2 
(Hs00183386_m1), CDH1 (Hs01023894_m1), CLDN1 (Hs00221623_m1), CLDN7 
(Hs00600772_m1), ESRP1 (Hs00214472_m1), INADL (Hs00195106_m1), LLGL2 
(Hs00189729_m1), OCLN (Hs00170162_m1), ST14 (Hs01058386_m1) were 
performed using the TaqMan Gene Expression Master Mix (Applied Biosystems, Foster 
City, CA, USA). RNA expression values were normalized versus the housekeeping 
gene RPLPO (Large Ribosomal Protein). The reaction was performed in a CFX384 
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Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). Quantitative real-
time PCR (qRT-PCR) analyses of hsa-miR-200b 002251, -200c 002300, -142-3p 
000464, -23a 000399, -150 000473, and -342-3p 002260 were performed by using 
miRNA-specific TaqMan MicroRNA Assay Kit (Applied Biosystems). RNU44 001094 
small RNA was used for normalization of input RNA/cDNA levels. ZEB1 expression 
was analyzed by using primers forward 5’-GCCAATAAGCAAACGATTCTG-3’ and 
reverse 5’-TTTGGCTGGATCACTTTCAAG-3’. Values were normalized versus 
housekeeping gene succinate dehydrogenase complex subunit A (SDHA), forward 5’-
TGGGAACAAGAGGGCATCTG-3’ and reverse 5’-
CCACCACTGCATCAAATTCATG-3’. All experiments were performed at least three 
times using triplicates. 
 
Western blot 
Western blot was performed as previously described.7 Proteins were analyzed by using 
the Odyssey Infrared Imaging or revealed following the ECL technique (Amersham, 
Buckinghamshire, UK). Different exposure times of the films were used to ensure that 
bands were not saturated. Western blots in all figures correspond to a representative 
experiment of at least three performed. Quantification of the experiments is indicated in 
each figure. 
 
Immunofluorescence and confocal microscopy 
Tissue Microarrays (TMA) corresponding to human colorectal (CRC) tumors at Stage 
III, from a collection available in the Pathology Service of the Vall d´Hebron Hospital, 
were chosen since the protein markers evaluated could potentially have predictive value 
on cancer progression. Previous data in CRC indicate that the probability of SPRY2 
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expression is around 0.90. If the probability of SPRY2-mediated ZEB1 overexpression 
exposure among cases is 0.80, we will need to study 33 cases patients to be able to 
detect the association between SPRY2 and ZEB1, with a power of 0.90 and two-sided 
error of 0.05. We used an uncorrected χ2 statistic to evaluate this hypothesis (PS Power 
and Sample Size Calculation v3.0). TMA were prepared and immunolabeled as 
described elsewhere.54 Briefly, antigens were retrieved by microwaving in 10 mM 
citrate buffer (pH 6.0) for 10 min and permeabilized with 0.2% Triton X-100 (Sigma-
Aldrich). Non-specific binding was blocked by incubating the sections in 10% BSA 
(Sigma-Aldrich) for 1 h. Cell imaging was performed on a Leica TCS SP5 DMI6000 
microscope using argon ion (488 nm), HeNe (543 nm) and violet diode (405 nm) lasers. 
Images were acquired sequentially by direct register using Leica Confocal Software 
(LAS AF). Fluorescence image data were analyzed with the MBF "ImageJ for 
Microscopy"-program collection of plugins (www.macbiophotonics.ca), using criteria 
described earlier.55 Briefly, we defined Regions of Interest (ROI) in images of 
immunostained tissues encompassing only tumoral tissue. First, using ImageJ software, 
we obtained the integrated density value and each channel-molecule (SPRY2, red 
channel; ZEB1 or claudin-7, green channel) and Hoechst 33342 (blue channel) for each 
ROI. Next, we measured the integrated density for Hoechst signal present in each ROI 
and normalized by a standard nucleus signal, defined as the average integrated density 
of ten nuclei taken at random. The resulting values correspond to the number of nuclei 
and, therefore, to the number of cells present in each ROI. Finally, we divided the 
values of the integrated density for each protein of interest (green or red channels) by 
the calculated number of cancer cells in the corresponding ROI. These values indicate 
the level of expression for each protein per cancer cell analyzed noted as relative units 
(r. u.) in the corresponding figures. 
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Gene expression analysis 
Microarray analyses were performed using RNAs obtained from Mock, SPRY2-wt, 
SPRY2-S112A and SPRY2-Y55F cells in three independent experiments performed in 
triplicate. Total RNA was extracted following manufacturer's instructions (Macherey-
Nagel). RNA integrity was assessed using Agilent 2100 Bioanalyzer (Agilent, Palo 
Alto, CA, USA). Total RNA samples were then processed for hybridization on Gene 
Chip Human Gene 1.0 ST Array (Affymetrix, Santa Clara, CA, USA) using standard 
Affymetrix protocols at the Genomics and Proteomics Facility of Centro de 
Investigación del Cáncer (Salamanca, Spain). Scanning was performed using GeneChip 
System of Affymetrix (GeneChip Hybridization Oven 640, GeneChip Fluidics Station 
450 and GeneChip Scanner 7G). The Robust Microarray Analysis (RMA) algorithm 
was used for background correction, intra- and inter-microarray normalization, and 
expression signal calculation.56 The absolute expression signal for each gene was 
calculated for each microarray. The expression signal was calculated using the CDF 
package called GeneMapper from GATExplorer (genemapperhumangene1.0cdf; see 
webite: http://bioinfow.dep.usal.es/xgate/ mapping/mapping.php),57 which maps into an 
updated version of human genes, instead of using the original probe-set definition 
provided by Affymetrix. This mapping provides an improvement thanks to the re-
annotation to updated gene loci and removal of cross-hybridation noise.57 It also allows 
us to operate from the beginning using gene identification (Ensembl IDs) instead of 
probe sets (Affymetrix IDs). Mapping to genome version Ensembl v57 (assembly 
GRCh37) was used for these analyses. 
 Analysis for differential expression was performed using the R platform for 
statistical analysis (R Development Core Team (2010). R: A language and environment 
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for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 
ISBN 3-900051-07-0, URL http://www.R-project.org/), and several packages from the 
Bioconductor project58 (http://www.bioconductor.org/). The raw data were imported 
into R and preprocessed using the affy package and the robust multichip average 
method. Further, Pearson correlation test and Principal Component Analysis (PCA) 
were carried out with all genes included in the dataset. To identify differentially 
expressed genes, we used the limma package. Correction for multiple testing was 
accomplished by controlling the false discovery rate (FDR) using published methods 
(FDR = 0.1).59 The experimental settings and raw data obtained in this experiment are 
deposited in GEO (accession number GSE56941). 
 
Functional Enrichment Analysis 
Single Enrichment Analysis (SEA) was performed with differentially expressed genes 
between conditions. This analysis was carried out with the functional annotation tool 
included in the DAVID Bioinformatics Resources. We considered only pathways with a 
Benjamini P value lower than 0.05 for the Kyoto Encyclopedia of Genes and Genomes 
(KEGG), REACTOME, and Gene Ontology – Biological Process databases. We used 
Gene Set Enrichment Analysis (GSEA)60 (www.broadinstitute.org/gsea) to assess the 
degree of association between our signature (expression data set) and some other 
signatures previously defined with genes significantly enriched in adhesion (gene sets: 
REACTOME Adherens_junctions_interactions, Gene Ontology: 0005911 Intercellular 
junctions, Gene Ontology: 0030054 Cell_junctions, KEGG Adherens junctions, KEGG 
tight junctions, KEGG gap junctions). GSEA requires ranking genes according to their 
association with a given phenotype, and determining whether genes in a signature tend 
to present either high (positively enriched) or low ranks (negatively enriched). The 
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output of GSEA is an enrichment score (ES), a normalized enrichment score (NES) 
which accounts for the size of the gene set being tested, a P-value and an estimated 
FDR. ES, NES and FDR were obtained as proposed previously.60 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Instat (GraphPad Software, San 
Diego, CA, USA). All experiments and qRT-PCR analyses were performed at least 
three times using triplicates. Significant differences between groups, expressed as mean 
± standard error of the mean (s.e.m), were calculated by parametric one-way ANOVA 
using Tukey-Kramer post-test, and correlation coefficients (r) were calculated by no 
parametric Spearman’s test. Homogeneity of variances between groups was analyzed 
using Brown-Forsythe test (n.s. P > 0.05). The single asterisk indicates P < 0.05, the 
double asterisk P < 0.01, and the triple asterisk P < 0.001. P > 0.05 were considered not 
significant (n.s.). 
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FIGURE LEGENDS 
 
Figure 1. SPRY2 represses epithelial adhesion and polarity genes. (a) Left, phase-
contrast images of Mock, SPRY2-wt, SPRY2-S112A and SPRY2-Y55F cells. Scale 
bar, 50 μm. Right, Western blot analysis of the expression of the AU5-tagged SPRY2 
proteins. Lamin B was used as loading control. (b) Quantitative RT-PCR analysis of 
CDH1, CLDN7, OCLN, CLDN1 and ZEB1 RNA levels, and (c) Western blot of ZEB1, 
E-cadherin, claudin-7, claudin-1 and occludin proteins in Mock, SPRY2-wt, SPRY2-
S112A and SPRY2-Y55F cells. (d) Quantitative RT-PCR analysis of ESRP1, ST14, 
INADL, LLGL2 and EPCAM RNA levels, and (e) Western blot of ST14 and EpCAM 
proteins in Mock, SPRY2-wt, SPRY2-S112A and SPRY2-Y55F cells. (f) Reporter 
assay in Mock and SPRY2-wt cells co-transfected with plasmids encoding a fragment (-
1136/+428 bp) of the CLDN7 gene upstream the luciferase cDNA or empty vector 
(pGL3) and ZEB1 cDNA or empty vector (pCDNA3). The graph shows the corrected 
luciferase activity values represented as fold change over the activity obtained in cells 
transfected with CLDN7 empty vector (pGL3) (n = 3). 
Figure 2. Mock- and SPRY2-S112A-cell signature predicts cellular adhesion versus 
SPRY2-wt signature. Genes are ranked according to their differential expression 
between Mock versus SPRY2-wt cells (left), SPRY2-S112A versus SPRY2-wt cells 
(middle), Mock versus SPRY2-S112A cells (right). Gene set enrichment analysis 
(GSEA) results for the enrichment of this gene set (GEO accession: GSE56941) 
detected toward the data sets: adherens junctions (KEGG pathways), intercellular 
junctions (Gene Ontology (GO): 0005911) and cell-to cell and extracellular matrix 
junctions as “cell junctions” (GO: 0030054). Black bars below the graph depict the 
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position of genes significantly enriched. ES, enrichment score; NES, normalized 
enrichment score; FDR, false discovery rate. NS, not significant. 
 
Figure 3. ZEB1 knock-down has opposite effects than SPRY2 expression on cell 
adhesion and polarity genes. (a) Quantitative RT-PCR analysis of RNA and (b) 
Western blot analysis of several adhesion and polarity genes/proteins in Mock cells 
transfected with control (non-silencing, NS; Mock-NS) or ZEB1 shRNA (pool and 
clone #7). (c) Quantitative RT-PCR analysis of miR-200b and miR-200c expression in 
Mock-NS or ZEB1 shRNA cells. (d) Quantitative RT-PCR analysis of RNA and (e) 
Western blot analysis of adhesion and polarity genes/proteins in SPRY2-wt cells 
transduced with NS or three different ZEB1 shRNA lentivirus (sh1, sh2 and sh3). (f) 
Quantitative RT-PCR analysis of miR-200b and miR-200c expression in SPRY2-wt 
transduced with NS or ZEB1 shRNA. (g) Reporter assay in control (NS) and ZEB1 
knocked-down (sh1 and sh2) SPRY2-wt cells transfected with CLDN7, CDH1 
promoters and empty plasmid pGL3. Graphs show corrected luciferase activity values 
represented as fold change over the activity obtained in cells transfected with empty 
vector (pGL3) (n = 3). 
 
Figure 4. SPRY2 expression correlates directly with that of ZEB1 and inversely 
with that of claudin-7 in human colon tumors. (a) Representative images showing 
protein expression by double immunofluorescence and confocal microscopy of ZEB1 
(green), and claudin-7 (green) in patients with high (patient 1) or low (patient 2) SPRY2 
expression (red). Nuclei were stained with Hoechst 33342 (blue). Scale bars: 100 μm. 
(b) Scatter plots showing the corresponding intensity correlation analyses of SPRY2 vs 
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ZEB1 (left), ZEB1 vs claudin-7 (middle) and SPRY2 vs claudin-7 (right). Statistical 
analysis was determined by non-parametric Spearman’s test. 
 
Figure 5. Repression of miR-200 and other miR species by SPRY2. (a) Putative 
binding sites for evolutionarily conserved miR species predicted by in silico analysis of 
ZEB1-RNA-3’UTR region using TargetScan, miRANDA and PicTar algorithms. Venn 
diagram showing common sites found. (b) Quantitative RT-PCR analysis of expression 
level of the indicated miRs in Mock (white columns) and SPRY2-wt (black columns) 
cells. miR-RNU-44 was used as internal control (all panels). (c) RNA levels of miR-
200b and miR-200c in Mock and SPRY2-wt, SPRY2-S112A and SPRY2-Y55F cells. 
(d) Reporter assay of HEK293T cells co-transfected with a ZEB1-RNA-3’UTR 
luciferase plasmid construct and mimic oligonucleotides (white columns, 5 nM; black 
columns, 50 nM) of miR-200b, miR-142-3p, miR-23a, miR-150, or a negative control 
(scrambled, Scr) (n = 3). (e) Left, description of wild-type and mutated binding 
sequences for miR species in ZEB1-RNA-3’UTR used in the following studies. Right, 
reporter assay of HEK293T cells co-transfected with a plasmid containing ZEB1-RNA-
3’UTR luciferase construct mutated in the predicted sites for miR-200 family, miR-150 
or miR-142-3p, and with mimic oligonucleotides of miR-200b, miR-142-3p, miR-150 or 
Scr (n = 3). (f) Quantitative RT-PCR analysis of ZEB1 RNA levels in Mock and 
SPRY2-wt cells that were transfected with mimic oligonucleotides of miR-200b, miR-
142-3p, miR-150, miR23a or Scr. (g) Western blot analysis of the expression of ZEB1, 
E-cadherin, and claudin-7 proteins in Mock and SPRY2-wt cells that were transfected 
with mimic oligonucleotides of miR-200b, miR-150, miR-142-3p, miR23a or Scr. AU5 
and Lamin B were used as control. (h) Activity of the miR-200c (-683/-67) and miR-
200b/a (-321/+120) promoters in Mock and SPRY2-wt cells transfected with plasmids 
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expressing ZEB1 or an empty vector (pCDNA3) (n = 3). (i) Left, activity of the miR-
200c and miR-200b/a promoters in SW480-ADH cells transiently transfected with 
expression plasmids for SPRY2 and ZEB1 or their empty vector (pCDNA3) (n = 3). 
Right, Western blot analysis of ZEB1 protein in transfected cells. In reporter assays, 
graphs show corrected luciferase activity values represented as fold change over the 
activity obtained in cells transfected with control vector of miR-200c and miR-200b/a 
(pGL3). 
 
Figure 6. Mechanism of SPRY2 action. (a) Western blot analysis (left) and 
quantification (right, n = 3) of phospho(p)-ERK proteins normalized to total ERK in 
serum-starved (overnight) Mock and SPRY2-wt cells at different times of treatment 
with 100 ng/mL EGF (+) or vehicle (-).Lamin B protein was used as loading control. (b) 
Western blot analysis of p-AKT in serum-starved Mock and SPRY2-wt cells at different 
times of treatment with 100 ng/mL EGF (+) or vehicle (-). (c) Western blot analysis of 
ZEB1, p-AKT and p-S6 proteins in SPRY2-wt cells treated with increasing doses of 
wortmannin or MK2266 for 24 h. Total AKT, S6, lamin B and AU5 antibodies were 
used as controls. (d) Western blot analysis (left) of ZEB1, E-cadherin and claudin-7 
proteins in Mock and SPRY2-wt cells treated with 5 μM PP2A (+) or vehicle (-) for 24 
h (left), and quantification of ZEB1 expression (n = 4) (right). (e) Western blot analysis 
of ETS1 protein in Mock, SPRY2-wt, SPRY2-S112A and SPRY2-Y55F cells. (f) 
Western blot analysis of ETS1 and ZEB1 proteins in Mock and SPRY2-wt transduced 
with two different shRNA lentiviruses for ETS1 (sh1 and sh2) and control (NS). (g) 
Western blot analysis of ETS1 and ZEB1 proteins in Mock and SPRY2-wt cells after 
ZEB1 silencing (sh1 and sh2). (h) Western blot analysis of ETS1 and ZEB1 proteins in 
SW480-ADH cells transiently transfected with and expression vector for human ETS1 
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cDNA. Lamin B was used as loading control. (i) Scheme of the mechanism of action of 
SPRY2 in colon carcinoma cells. 
 










